Standards efforts and landscape for rapid microbial testing methodologies in regenerative medicine
Abstract
The Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-Based Drug Discovery (SCB) supports the development and commercialization of regenerative medicine products by identifying and addressing industry-wide challenges through standards. Through extensive stakeholder engagement, the implementation of rapid microbial testing methods (RMTMs) was identified as a high-priority need that must be addressed to facilitate more timely release of products. Since 2017, SCB has coordinated efforts to develop standards for this area through surveys, weekly meetings, workshops, leadership in working groups and participation in standards development organizations. This article describes the results of these efforts and discusses the current landscape of RMTMs for regenerative medicine products. Based on discussions with stakeholders across the field, an overview of traditional culture-based methods and limitations, alternative microbial testing technologies and current challenges, fit-for-purpose rapid microbial testing and case studies, risk-based strategies for selection of novel rapid microbial test methods and ongoing standards efforts for rapid microbial testing are captured here. To this end, SCB is facilitating several initiatives to address challenges associated with rapid microbial testing for regenerative medicine products. Two documentary standards are under development: an International Organization for Standardization standard to provide the framewor…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
As therapies move beyond phase I trials, meeting requirements for a strictly controlled environment becomes more costly and time-consuming.
“As these therapies move beyond phase I trials, meeting these requirements becomes more costly and time-consuming (129,130).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [130]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 30 · Cited by 12
- Authors
- Lin-Gibson, S., Lin, N. J., Jackson, S., Viswanathan, S., Zylberberg, C., Wolfrum, J., Basu, S., Roy, K., Marshall, D., McFarland, R., Hoover, S., Rietze, R., Getz, A., & Henke, D.
- Affiliations
- National Institute of Standards and Technology (US)
- University Health Network (CA)
- Massachusetts Institute of Technology (US)
- Georgia Institute of Technology (US)
- Cell and Gene Therapy Catapult (GB)
- Corresponding author
- Henke, Dawn
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 23
- Issue
- 5
- Pages
- 390-398
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W3147384789
- Cited by
- 12
- References
- 30
- Citations by year
- 2026: 5 · 2025: 3 · 2023: 2 · 2021: 2
- FWCI
- 0.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cytotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Standards and Technology
- National Institute for Innovation in Manufacturing Biopharmaceuticals
- Topics
- Health Sciences › Medicine › Physiology › Biomedical Ethics and Regulation
- Health Sciences › Health Professions › Health Information Management › Healthcare Regulation
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- rapid microbial testing, regenerative medicine products, standards development, cell and gene therapy, tissue engineered medical products, interlaboratory testing
- MeSH terms
- Biological Assay, Reference Standards, Tissue Engineering, Regenerative Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review